Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Active Relapsing Multiple Sclerosis (PRO-MSACTIVE)
NCT03589105Phase 4Completed
- Sponsor
- Roche
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Percentage of participants free of disease activity (No Evidence of Disease Activity) at 48 weeks. Started Aug 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03589105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589105.